The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis

Tocilizumab (Actemra) is a humanized anti-interleukin-6 receptor antibody that has been used as a steroid-sparing agent in giant cell arteritis (GCA). Although the clinical effects are well described in GCA, the cost-effectiveness of the use of tocilizumab in GCA is ill defined. The purpose of this...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-ophthalmology 2021-09, Vol.41 (3), p.342-350
Hauptverfasser:	Jogimahanti, Arjun V., Kini, Ashwini T., Irwin, Lauren E., Lee, Andrew G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Biopsy Combined Modality Therapy Cost-Benefit Analysis Drug Costs Female Follow-Up Studies Giant Cell Arteritis - diagnosis Giant Cell Arteritis - drug therapy Glucocorticoids - therapeutic use Humans Male Middle Aged Prednisone - therapeutic use Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!